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Abstract 
Bismuth has been used in medicine for over two centuries for the treatment of various diseases, 
in particular for gastrointestinal disorders, owing to its antimicrobial activity. Recent structural 
characterization of bismuth drugs provides an insight into assembly and pharmacokinetic 
pathway of the drugs. Mining potential protein targets inside the pathogen via 
metallomic/metalloproteomic approach and further characterization on the interactions of 
bismuth drugs with these targets laid foundation in understanding the mechanism of action of 
bismuth drugs. Such studies would be beneficial in rational design of new potential drugs.  
 
Introduction 
Bismuth compounds have been used in medicine for more than 200 years for the treatment of 
various diseases including syphilis, hypertension, infections, skin conditions, and gastrointestinal 
disorders [1, 2●]. The discovery of Helicobacter pylori (H. pylori), a Gram-negative bacterium 
from gastric mucosa which is responsible for gastric and duodenal ulcers [3], has further 
promoted both research and medical applications of bismuth. Currently, three bismuth drugs i.e. 
bismuth subsalicylate (Pepto-Bismol
®
), colloidal bismuth subcitrate (De-Nol
®
), and ranitidine 
bismuth citrate (Tritec
®
 and Pylorid
®
) are being used worldwide in combination with antibiotics 
to eradicate H. pylori infection. In addition, many new bismuth compounds with different 
structures and activities as well as bismuth nanotubes have been synthesized [2●, 4, 5].  
 
For the past few years, enormous efforts have been made towards understanding the structures [6, 
7●●,8] as well as the mechanism of actions of the bismuth drugs [2●]. Recent advances in 
biophysics and molecular biology have provided invaluable tools necessary to study the 
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bioinorganic chemistry of bismuth. For example, time-resolved inductively coupled plasma mass 
spectrometry enables bismuth antiulcer drugs to be tracked in single Helicobacter pylori cells (ca. 
1.0x10
6
 Bi atoms/cell). The uptake of bismuth by Helicobacter pylori is retarded by ferric ions 
(Fe
3+
) suggesting that bismuth drugs may utilize certain iron-transport pathways in the pathogen 
[9]. A number of protein targets of bismuth drugs, in particular those from the H. pylori have 
been identified by metallomic and metalloproteomic approach [10●, 11]. Several comprehensive 
reviews summarized the chemistry and biological chemistry of bismuth as well as its medical 
applications are available recently [1, 2●, 6, 11, 12].  Here we will only focus on some recent 
advances in the structures and protein targets of bismuth drugs as well as design of potentially 
active new bismuth complexes.    
 
Structural models of bismuth drugs  
In spite of extensive clinical usage of bismuth drugs, the structures of these drugs have not been 
unveiled until the last two decades. Various bismuth citrate complexes with different bismuth to 
citrate ratios have been crystallized at different pH values. Among these, the structure obtained 
under acidic condition (pH 3) most likely represents real situation in the stomach [13]. Colloidal 
bismuth subcitrate (CBS) is likely to assemble into sheets and then three-dimensional polymers 
using bismuth citrate dinuclear units [Bi(cit)2Bi]
2-
 as building blocks to form a protective coating 
on the ulcer craters [13].  
 
Crystal structures of four bismuth citrate complexes obtained at the acidic pH values in the 
presence of either ethylenediamine or pyridine [14] reveal that bismuth citrate dimeric units 
[Bi(cit)2Bi]
2- 
(Figure 1A) serve as the basic building blocks leading to polymeric structures with 
regular meshes and internal cavities. The protonated ethylenediamine, despite unobservable in 
the structure (Figure 1B), and pyridine moieties (Figure 1C) are embedded probably by diffusion 
or electrostatic interaction in the polymeric framework to achieve charge balance since all citrate 
anions found in the structures are deprotonated leading to citrate tetrannions ([C6H4O7]
4-
). The 
composition of the bismuth citrate complex frameworks depends on the size and level of 
protonation of the inserted cations, the pH values as well as the time of crystallization. The 
structural model of ranitidine bismuth citrate (RBC) was constructed based on the framework of 
crystal structure of complex 1 [14]. Ranitidine molecules can be readily embedded into the 
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cavities perpendicular to the bc plane with H-bonds formed between ranitidine and the bound 
citrate ligands, Figure 1D.  In addition, the sulfur atoms of ranitidine form H-bonds with a water 
molecule that coordinates to bismuth. Based on X-ray crystal structures as well as ESI-MS of 
bismuth citrate complexes, it is likely that bismuth citrate-based drugs degrade under gastric 
acidic condition (pH ~3), from 3-D polymer framework to 2-D polymeric sheets and finally to a 
basic dimeric unit such as [Bi(cit)2Bi]
2- 
which can be absorbed or transported by membrane 
receptors.  
 
Bismuth subsalicylate (Pepto-Bismol
®
, BSS) is one of the most commonly used bismuth drugs 
[11]. Structural characterization of bismuth carboxylates is a challenging due to difficulties in 
controlling hydrolysis of these complexes or the formation of coordination oligomers/polymers. 
Recently, structures [Bi38O44(Hsal)26(Me2CO)16(H2O2)]·(Me2CO4) and 
[Bi9O7(Hsal)13(Me2CO)5]·(Me2CO)1.5 (Figure 1E) may provide an insights into the nature of BSS 
and a basis for studies the mode of action of the drug [8]. The crystals of  
[Bi9O7(Hsal)13(Me2CO)5]·(Me2CO)1.5 initially predominate with only relative small amounts of 
the large cluster with 38 bismuth atoms which appeared to be the least soluble and most 
thermodynamically stable form when extending crystal growth times. The structure contains a 
basic building block [Bi6O8]
2+
 polyhedron as found in other bismuth oxo clusters [15], which 
have six octahedral Bi atoms with the eight O atoms located over all of the triangular faces. The 
cores of the two structures are the Bi9 clusters comprised of a central Bi6 octahedron but with 
only seven of the eight trigonal faces capped by an O atom as shown in Figure 1F. In both 
structures, bismuth also coordinated to the solvent molecules of acetone, which can be replaced 
by other solvent molecules such as DMF (dimethyflormamide) when crystallized in this solvent 
[7●●]. Interestingly, the core of [Bi9O7(Hsal)13(Me2CO)5]·(Me2CO)1.5 lies at the heart of 
[Bi38O44(Hsal)26(Me2CO)16(H2O2)]·(Me2CO4) combined with the presence of Bi-coordinated 
solvent molecules in these structures reveals a possible process for hydrolysis and core formation, 
and indicates that the complex  [Bi9O7(Hsal)13(Me2CO)5]·(Me2CO)1.5  gave rise to the complex 
[Bi38O44(Hsal)26(Me2CO)16(H2O2)]·(Me2CO4). 
 
The first structure of BSS without organic auxiliaries obtained from X-ray diffraction data of 
bismuth disalicylate powder [7●●] gave rise to  two-dimensional polymers held by Bi-O linkages 
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and O-H···O hydrogen bonds with one bismuth atom, one salicylate mono-anion and one 
salicylate dianion in each unit. The monoanionic salicylate coordinates to a single Bi
3+
 ion 
through its carboxylate group only and the dianionic salicylate employs the phenoxide oxygen 
atoms as bridging ligands to form four-membered Bi2O2 rings. An additional oxygen atom from 
a water molecule is bonded to bismuth. Such a structure of BSS resembles bismuth complexes 
with substituted benzoic acids [16].   
 
New bismuth complexes and their activities  
Over the last decade, significant work has been devoted into the development of new bismuth 
drugs [2, 17, 18]. Various new bismuth-containing complexes have been synthesized and showed 
promising in vitro activities against H. pylori [17, 18]. Importantly, some bismuth-containing 
complexes have been demonstrated to exhibit new in vitro activities including antifungal, 
antiviral or even anticancer activities [19-24]. 
 
Bismuth drugs such as BSS, CBS and RBC are effective in treating and eradicating Helicobacter 
pylori together with antibiotics. However, these non-steroidal anti-inflammatory drugs (NSAIDs) 
may also cause gastrointestinal damage. Bismuth derivatives of NSAIDs exhibited good in vitro 
activity against the three strains of H. pylori with the minimum inhibitory concentrations (MIC) 
 6.25 g/mL, which are better than commercially used BSS (8 g/mL), laboratory prepared 
bismuth salicylate (12.5 g/mL) and CBS (12.5 g/mL) [18]. Therefore, these compounds 
may have great potential in the treatment of H. pylori infection while allowing the concomitant 
therapeutic benefits of NSAID treatment. Similarly, heteroleptic bismuth sulfosalicylate 
complexes [PhBi(HSsal)H2O] and [PhBi(HSsal)H2O] as well as bis-phenylbismuth sulfonates  
[Ph2Bi(O3SR)] (R=p-toly, mesityl or S-(+)-10-camphoryl) [17, 25] showed significant activities 
against H. pylori with MIC< 6.25 g/mL. Some cyclic organobismuth compounds bearing a 
nitrogen or sulfur atoms as additional ring member also exhibit various antibacterial activities 
including gram-positive and gram-negative bacteria [26]. Although these bismuth-containing 
complexes showed in vitro activities against H. pylori and other pathogens, there appears to be 
lack of in vivo data and more works are warranted to promote medical application of these 
complexes. 
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Beside antibacterial activity, bismuth complexes of substituted benzoic acids also exhibit 
significant anti-Leishmanial activity against the promastigotes of L. major V121 [27]. 
Heterocyclic organobismuth compounds [ClBi(5-R-C6H3-2-SO2C6H4-1´-) (R=Me, Ph, MeO, Cl, 
H, t-Bu, CF3, F, Me2N) exert antifungal activities against Saccharomyces cerevisiae and the 
activity depends on the lipophilicity of the compounds: the higher the lipophilicity, the lower the 
antifungal activity [19]. Some organobismuth compounds have been also found to exhibit anti-
tumor potentials [2, 24]. Bismuth xanthate complexes [Bi(S2COR)3] (R=Et, i-Pr, cyclohexyl) 
were shown to exert cytotoxic activities against Calu-6 (lung adenocarcinoma) with a similar 
IC50 values of cisplatin [28], indicating that these compounds have potency comparable to 
cisplatin. Moreover, these bismuth complexes also exerted cytotoxic activities against cisplatin-
insensitive MCF-7 (mammary carcinoma) [28]. Bismuth dithiocarbamate complexes with 
general formula of [Bi(S2CNR2)] were also demonstrated to exhibit potent in vitro cytotoxicity 
against a panel of seven human cancer cell lines [23]. Some heterocyclic organobismuth 
compounds have potent cytotoxic activities against various cancer cell lines with IC50 in the 
range of 0.059-5.1 M, in particular, are sensitive towards leukemic cell lines [20, 29]. These 
bismuth compounds such as bi-chlorodibenzo[c,f][1,5]thiabismocine may induce apoptosis in 
HL-60 cells through the activation of caspase, production of ROS, and perturbation of 
mitochondria [20], they may also target tubulin to induce G2/M arrest in HeLa cells probably by 
interacting with the colchicines-binding site through its thiolate (-SH) groups [29]. This type of 
organobismuth compounds may be utilized as antimitotic agents and in the treatment of 
refractory acute promyelocytic leukemia similar to arsenic trioxide.  
 
The antiviral activity of bismuth complexes was explored over the severe acute respiratory 
syndrome coronavirus (SARS-CoV), an enveloped, single-stranded RNA positive-strand virus 
that killed hundreds of people worldwide when is broken out in 2003 [30]. A series of bismuth 
complexes including bismuth nitrilotriacetate Bi(NTA), bismuth tricysteine Bi(Cys)3, ranitidine 
bismuth citrate (RBC), bismuth ethylenediaminetetraacetate (Bi(EDTA)) as well as bismuth 
complexes with various N,O-containing chelate ligands including bismuth porphyrin complexes 
were examined against the SARS-CoV helicase [21, 22], which was postulated to be the 
potential target for anti-SARS therapy [30]. The majority of bismuth complexes tested exhibited 
activities against SARS-CoV helicase ATPase and duplex-unwinding activities with the highest 
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activities found for RBC and bismuth porphyrin complexes at IC50 values of less than 1 M. 
Bi(EDTA) and other two bismuth complexes with N, O-containing chelate ligands showed 
almost no activity, indicating that different inhibition activities of these complexes are correlated 
to their different coordination environments, i.e. the higher affinity of bismuth towards the 
chelate ligands, the lower activities. The treatment of SARS-CoV infected cells by bismuth-
containing complexes such as RBC and Bi2-hTF (hTF=human transferrin) confirmed an 
inhibitory role of bismuth during later stages of the replicative cycle [22]. The studies represent 
the first attempt in using bismuth as anti-virus agent although further work is required to 
elucidate such activities.       
 
Potential protein targets of bismuth drugs 
The mechanism of action of bismuth drugs is complicated and not fully understood. It is 
generally believed that bismuth drugs are taken up into gastric mucus to form a protective 
coating probably as BiOCl and bismuth citrate complexes on the ulcer crater. They may inhibit 
Helicobacter pylori adherence and also bind strongly to connective tissue proteins, mucus 
glycoproteins and enzymes [1, 2]. Accumulative studies demonstrated that proteins (peptides) 
are likely to be the potential targets of the drugs. Bismuth drugs have been shown to interact with 
a range of proteins such as human serum transferrin [31, 32], lactoferrin [33], serum albumin [32, 
34], and metallothionein [35]. The binding of bismuth to lactoferrin may deprive of iron 
acquisition of H. pylori since the bacteria utilize host-specific lactoferrin for iron acquisition [36]. 
The level of bismuth uptake by H. pylori single cell is also found to be reversibly correlated to 
the level of iron [9]. Bismuth drugs have also been demonstrated to inhibit several enzymes from 
H. pylori.  It inhibits the activity of yeast alcohol dehydrogenase by interfering with the zinc site 
and altering enzyme native structures [37]. Once bismuth is up-taken by the pathogen H. pylori, 
it may target several proteins inside the pathogen to inhibit synthesis of essential enzymes such 
as urease and hydrogenease or other nickel-binding proteins, which are critical for bacterial 
survival. Very recently, the metallomics/metalloproteomics approach has been used to 
investigate the role of metals in biological systems [38●, 39●] and to search for putative binding 
proteins (targets) of bismuth drugs inside the bacterium [10, 40, 41]. The recent advances in this 
area are updated since other information has been summarized elsewhere [1, 2, 6, 11].    
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Urease, accountable for up to 10% of the total cellular proteins, is an essential nickel-containing 
enzyme for H. pylori colonization and virulence. It catalyzes the hydrolysis of urea to yield 
carbamate and ammonia and thus neutralizes its immediate environment of the bacterium to aid 
its survival under acidic conditions of the gastric lumen and mucosa. Bismuth complexes such as, 
RBC as well as some triarylbismuthanes can inhibit urease activity [42, 43]. Inhibition of jack 
bean urease by the triarylbismuthanes compounds is in good agreement with observed 
antibacterial activity of the compounds against H. pylori [43]. Both Bi(EDTA) and Bi(Cys)3 are 
competitive inhibitors of jack bean urease, while RBC is a non-competitive inhibitor. Kinetic 
analysis demonstrated that Bi(EDTA) is both a competitive inhibitor and a time-dependent 
inactivator of the recombinant Klebsiella areogenes urease. Such an inhibition is likely due to 
the binding of bismuth to the cysteine residues of the enzyme (Cys319 in Klebsiella areogenes 
and probably Cys592 in jack bean urease) at the entrance of the active site [42].  
 
The survival of H. pylori requires a constant supply of Ni
2+
 ions for the synthesis and activities 
of the Ni
2+
-containing enzymes. Like other bacteria, H. pylori has to be able to strike a delicate 
balance between the import of Ni
2+
 ions, their efficient intracellular storage and delivery to Ni
2+
-
dependent metalloenzymes when required. H. pylori is able to synthesize a small histidine-rich 
cytoplasmic protein Hpn (28 histidine out of 60 amino acids) and histidine-rich glutamine-rich 
proteins Hpnl (18 histidine and 30 glutamine out of 71 amino acids), which may play roles of 
storage of nickel ions as a ‘reservoir’, donation of nickel to other proteins and detoxification via 
sequestration of excess nickel ions depending on the exogenous nickel levels [44-46]. Both in 
vitro and in vivo experiments suggested that Hpn and Hpnl sequester nickel ions at neutral pH 
but donate them probably for urease activation under acidic condition [44, 45, 47]. H. pylori 
lacking hpn/hpnl gene, cultured in vitro, are more susceptible to Ni
2+
 and Bi
3+
 than the wild-type 
strain. Both essential metal ions such as Ni
2+
, Zn
2+
, Cu
2+
 and therapeutic metal ions e.g. Bi
3+
 bind 
to Hpn in vitro, indicating that Hpn may serve as a potential target for bismuth therapy. Hpn 
binds ca. 4.80.2 Ni2+ and 3.80.2 Bi3+ per monomer probably via multiple imidazole groups 
and four Cys residues with dissociate constants (Kd) of 7.1 and 11.1 M respectively [47, 48], 
while Hpn-like (Hpnl) binds ca. 2.00.1 Ni2+ per monomer (Kd of 3.80.2 M) and two histidine 
residues (His29 and His31) were identified to play a critical role in binding of Ni
2+
 [45, 49]. 
Whether Hpnl interacts with bismuth drugs is not known and may warrant for studies. Recently, 
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fluorescence resonance energy transfer (FRET) approach has allowed studies of metal binding 
properties of Hpn (where the protein sequence is inserted between the FRET partners CFP and 
YFP) both in vitro and in vivo. It was found that when Hpn-FRET was expressed in a model 
system e.g. E. coli, FRET change was only observed with addition of bismuth subsalicylate 
(Pepto Bismol) but not Ni
2+
 and Zn
2+
, clearly indicating that Hpn is a potential target for bismuth 
in vivo [50●●]. The binding of bismuth to the protein may therefore interfere with its normal 
functions. 
 
Systematic identification of potential targets of metallodrugs is achievable nowadays by 
metallomic/metalloproteomic approach as shown in Figure 2A. Immobilized-metal affinity 
chromatography (IMAC) in combination with two dimensional electrophoresis (2-DE) and 
MALDI-TOF mass spectrometry is a particularly useful tool for elucidating the metabolism of 
intracellular metal ions and identifying molecular targets or binding proteins associated with the 
disease etiology and pathology for metallodrugs [10, 40]. This approach has been used for the 
first time to search the potential protein targets of bismuth drugs in H. pylori on a genome-wide 
scale. A comparative proteomic analysis of H. pylori cells before and after treatment of colloidal 
bismuth subcitrate (CBS) was performed [41]. Eight proteins were found to be significantly up- 
or down-regulated, Figure 2B. These proteins are mainly involved in either cellular processes 
(HspA, HspB, putative alkyl hydroperoxide reducase TsaA and neutrophil-activating protein 
NapA), or oxidative stress resistance (thioredoxin), and hemoglobin. The up-regulated 
expression of thioredoxin, a low redox potential reductant, may reflect the response of H. pylori 
to the high level of oxidative stress. Using immobilized-bismuth affinity chromatography (Bi-
IMAC), seven bismuth-binding proteins were subsequently identified from H. pylori cell extracts 
Figure 2C. Interestingly, the intracellular levels of four proteins e.g. HspA, HspB, NapA, TsaA 
were decreased upon addition of CBS, Figure 2C, suggesting that these proteins directly bind to 
bismuth. The other bismuth-binding proteins identified include fumarase and urease subunit 
UreB and a translational factor Ef-Tu. Furthermore, it was found that bismuth led to around 8-
fold decrease in cellular protease activity and elevated the levels of lipid hydroperoxide and 
hemin in the whole cell extract of bismuth-treated H. pylori cells than those untreated cells [41].  
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To validate the potential targets of bismuth drugs identified by metalloproteomic approach 
subsequent studies have been carried out [51,52●●,53]. For example, fumarase, an enzyme which 
catalyses the reversible hydration of fumarate to malic acid, binds one Bi
3+
 per monomer, leading 
to an apparent non-competitive inhibition of the enzyme [53]. HspA, a member of the GroES 
chaperonin family, is a small protein with a unique histidine/cysteine-rich domain at the C 
terminus with the sequence shown in Figure 3A. Apart from the normal function of GroES e.g. 
aiding protein folding in conjunction with GroEL, it also plays a role in nickel regulation: to 
facilitate nickel acquisition by donation of nickel to appropriate proteins (and enzymes), and to 
detoxificate excess nickel [51]. Recombinant HspA from H. pylori was found to bind about two 
Bi
3+
 ions (or two Ni
2+
) per monomer of the protein, Figure 3B, and the C-terminal Cys-Cys motif 
and histidine residues are likely involved in the binding, similar to Hpn [44, 48, 51, 54]. The 
potential roles of the His- and Cys-rich terminus in vivo was examined by comparison of the 
growth of E. coli cells expressing the wild type or C-terminal deletion mutant in M9 minimal 
medium supplemented with metal ions in a concentration-dependent manor [51]. E. coli cells 
expressing the C-terminal deletion mutant were more susceptible to increasing concentrations of 
nickel ions. In contrast, Bi
3+
 retarded the growth of the wild type-containing cells [51]. 
Surprisingly, apart from the C-terminal metal binding domain, three residues (His45, Cys51, and 
Cys53) are found to be critical for Zn
2+
 binding in vivo but not for other transition metal ions 
such as Ni
2+
, Cu
2+
, Fe
3+
, Mn
2+
 [52●●]. These residues are located at the N-terminal apical domain 
and were probably originated from negative selection (Figure 3D) and make up an oxidation-
sensitive zinc binding site since the Zn
2+
-bound HpGroESMBD restored the activity of enzyme 
alkaline phosphatase (AP). Equilibrium dialysis study showed that bismuth binds to the C-
terminal deleted HpGroES (HpGroESMBD) in a similar pattern to Zn2+ with an affinity 40-fold 
higher than that bismuth binding to the C-terminal metal binding domain [52●●]. Competition 
experiments between Bi
3+
 and Zn
2+
 reacting with HpGroESMBD indicated that bismuth is able 
to replace the bound zinc from the protein, Figure 3E. Significantly, the binding of bismuth to 
GroES altered its quaternary structure from its native heptamer to a dimer, which is attributable 
to bismuth binding to the N-terminal zinc-site, not the C-terminal metal binding domain, Figure 
3F. Taken together, once bismuth drugs entered the H. pylori, they may interfere with nickel 
homeostasis by binding to nickel storage proteins (Hpn/Hpnl), and accessory proteins (HspA) 
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responsible for hydrogenease or urease synthesis. The bismuth drugs are also likely to inhibit 
protease and urease activity; and modulate cellular oxidative stress.  
 
Conclusions and perspectives  
Bismuth drugs have been used clinically for its antimicrobial activity. Structural characterization 
of bismuth drugs shed light on assembly and decomposition of the drugs. Extensive studies have 
been carried out to explore other potentials of bismuth drugs and amazingly, bismuth also 
exhibits in vitro activities such as anti-Leishmanial activity, anti-tumor activity that both 
antimony and arsenic possess. Currently, no bismuth-containing compounds are in clinical trial 
for treatment of either cancer or viral infection. Nevertheless, some recent in vitro data are quite 
encouraging [20]. Further extensive explore may be needed in future. Moreover, pretreatment of 
bismuth drugs can reduce the side-effects of anticancer drugs such as cisplatin [55], which may 
also offer a potential for the application of bismuth in the treatment of cancer.  
 
In spite of extensive studies, our knowledge on the mechanism of action of bismuth drugs is still 
very limited. Accumulated data indicated that proteins (and enzymes) are likely to be the targets 
of bismuth drugs. The interactions of bismuth drugs with a number of proteins have been 
characterized individually. Recently, an integrated view on potential bismuth drugs inside H. 
pylori was given with the aid of metallomics/metalloproteomics approach. The strategy can 
readily be extended to study the mechanism of other metallodrugs as well as to evaluate uptake, 
storage and excursion of transition metal ions [10, 38].  
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Figure 1 Structures and structural models of bismuth citract and bismuth sub-subsalicylate 
(BSS). (A) Dimeric bismuth citrate building block with ball-stick model and polyhedral; (B) the 
polymeric framework of bismuth citrate linked by three types of bismuth citrate building blocks 
represented by adjacent green, blue and purple polyhedral respectively; (C) the two-dimensional 
polymeric structure of the polymeric framework with pyridine rings in the channels (represented  
as space-filling mode); (D) structural model of rantidine bismuth citrate with ranitidine inserted 
in the channel; (E) Core structure of bismuth sub-subsalicylate [Bi9O7(HSal)13((CH3)2CO)5] 
showing the shrouding of the Bi9O7 core by 13 salicylate ligands (stick structures) and (F)  
structure of the Bi9O7 core showing the octahedral arrangement of the bismuth atoms (ark brown 
balls) with seven octahedral faces capped by an oxygen atom (red balls). 
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Figure 2 (A) Schematic chart of metalloproteomics in identification of bismuth-binding 
(including bismuth) proteins and motifs. (B) Two-dimensional gel electrophoresis image of cell 
extracts of H. pylori (strain 11637) in the absence and presence of bismuth drugs. (C) Two-
dimensional gel electrophoresis image of fractions of cell extracts eluted from bismuth column 
from untreated and bismuth drug treated H. pylori cells, showing bismuth binding proteins, i.e. 
UreB, HspA, HspB, TasA, NapA and fumerase. 
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Figure 3 (A) Scheme of HspA with the putative metal binding domain highlighted. (B) Binding 
of bismuth to the protein was demonstrated by difference UV-vis spectra. (C) Bismuth but not 
nickel induces HspA from a heptamer to a dimer. (D) Negative selection of the three metal-
binding residues, His49, Cys51 and Cys53 as demonstrated in the position-specific polymorphy. 
The substitution modes are identified from the alignment of multiple Hspa (GroES) homologs, 
and the corresponding proportions of each substitute are shown by the height of the letters. (E) 
Proposed scheme showing the oligomeric state of HspA in the presence of bismuth. For clarity, 
only the front subunit is highlighted, and the rest are shaded in gray. 
